HG
AUTL

Herbst Group’s Autolus Therapeutics AUTL Stock Holding History

Herbst Group’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25,000
Closed -$57K – 52
2025
Q2 		$57K Hold
25,000
– – 0.03% 55
2025
Q1 		$38.8K Hold
25,000
– – 0.03% 52
2024
Q4 		$58.8K Hold
25,000
– – 0.04% 59
2024
Q3 		$90.8K Buy
+25,000
New +$99.7K 0.06% 57

Other funds holding AUTL

MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Herbst Group's AUTL Position: Q3 2025 in Review

Herbst Group sold out of Autolus Therapeutics (AUTL) in Q3 2025, closing a stake of 25,000 shares — an estimated $57K sold.

Herbst Group first reported a position in AUTL in Q3 2024 and held it in 4 quarters. The position peaked at $90.8K in Q3 2024. 96 funds tracked by Wall St. Rank hold AUTL as of Q3 2025.

  • Herbst Group reported no remaining Autolus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Herbst Group sold 25,000 Autolus Therapeutics shares in Q3 2025, an estimated $57K.
  • Herbst Group first reported a position in Autolus Therapeutics in Q3 2024 and held it in 4 quarters.
  • Herbst Group's Autolus Therapeutics position peaked at $90.8K in Q3 2024.
  • 96 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2025.

Based on Herbst Group's 13F filing for Q3 2025, filed 14 Nov 2025.